恩替卡韦联合大黄蛰虫丸治疗慢性乙型病毒性肝炎对肝纤维化指标的影响

目的:观察恩替卡韦联合大黄蛰虫丸治疗慢性乙型病毒性肝炎(CHB)对肝纤维化指标的影响。方法:140例CHB患者随机分为治疗组与对照组,分别给予恩替卡韦+大黄蛰虫丸、恩替卡韦治疗12个月。观察2组肝功能指标、肝纤维化血清学指标、不良反应发生情况。结果:治疗组与对照组的丙氨酸氨基转移酶复常率分别为88.9%、73.5%(P>0.05),总胆红素复常率分别为88.2%、91.7%%(P>0.05);治疗组治疗后玻璃酸、层黏蛋白、Ⅲ型前胶原、Ⅳ型胶原肽的下降幅度均明显大于对照组(P<0.05);治疗组有2例发生了轻度的药品不良反应。结论:恩替卡韦联合大黄蛰虫丸治疗更有利于阻滞或逆转肝纤维化的形成和发展。

Effect of Entecavir Combined with Dahuangzhechong Pills on Hepatic Fibrosis in Patients with Chronic Hepatitis B

OBJECTIVE： To observe the effect of Entecavir combined with Dahuangzhechong pills on hepatic fibrosis in patients with chronic hepatitis B （CHB） . METHODS： 140 CHB patients were randomly assigned to receive Enteeavir alone （control group） or Enteeavir in combination with Dahuangzhechong pills （trial group） for 12 months. The liver function parameters, the hepatic fibrosis indexes and the adverse drug effects in the two groups were observed. RESULTS： In the treatment group vs. the control group, the normalization rate of ALT （alanine aminotransferase） was 88.9% vs. 73.5%（P〉 0.05）, the normalization rate of total bilirubin（TBIL） was 88.2% vs. 91.7% % （P 〉0.05）. After treatment, serum hyaluronic acid（HA）, laminin （LN）, type Ⅲ precollagen, type Ⅳ collagen peptide decreased more significantly in the treatment group than in the control group（P〈0.05） . 2 cases in the trial group had mild adverse drug reactions. CONCLUSIONS： Entecavir combined Dahuangzhechong pills is more useful than either condition alone in preventing or reversing the formation and development of liver fibrosis.